NOTE. fHBP, factor H binding protein; NadA, Neisserial adhesin A; NHBA, Neisserial heparin binding antigen; x, does not harbor the NadA gene; Ϫ, low expression; +/Ϫ medium expression; + high expression; ++ very high expression.
a fHBP classification scheme used by Novartis Vaccines, which classifies into 1 of 3 variants based on similarity. Each variant contains multiple related subvariants [12] . b fHBP classification scheme according to http://www.neisseria.org, which classifies peptide variants with a sequential number on submission to the database. c Expression of antigen as determined by binding of murine antibody raised against the vaccine antigen(s). d GenBank accession number identifying unique sequence at http://www.ncbi.nlm.nih.gov.
cines are primarily directed against the immunodominant and variable PorA protein, which results in a limited ability to confer protection against heterologous meningococci [9] . Consequently, these vaccines have not been implemented in areas with polyclonal MenB disease, such as Europe and the United States. Analysis of the meningococcal genome enabled the identification of genes encoding novel proteins and led to the development of an investigational recombinant protein (rMenB) vaccine [10] . This vaccine contains a native protein, Neisserial adhesin A (NadA) and 2 fusion proteins, genome-derived Neisserial antigen (GNA) 2132-1030 and 2091-1870. NadA is involved in adhesion to human nasopharyngeal epithelium [11] and has 5 variants (and sub-variants) [12] . GNA 2132 has been renamed Neisserial heparin binding antigen (NHBA) because of its ability to bind heparin [13] and has 14 variants (and subvariants) [12] . GNA 1870 has been renamed factor H-binding protein (fHBP) because of its ability to bind human factor H [11] and has 3 variants (and sub-variants) [12] . The functions of GNA 1030 and 2091 are currently undetermined but act as accessory proteins in the fusion-antigens, increasing the stability and immunogenicity of NHBA and fHBP [10] . To broaden the immune response, the rMenB vaccine was formulated with OMVs produced from the New Zealand outbreak strain, NZ 98/254 (P1.7-2,4). In a phase I trial, 93%-100% of adults who received 3 doses of the combined vaccine attained putative protective serum bactericidal anitbody (SBA) titers у4 against MenB strains expressing fHBP, NadA, and PorA (P1.7-2,4) [14] .
Despite promising results in preclinical and phase I trials, a successful MenB vaccine must be capable of inducing an immune response in young infants, those at greatest risk of contracting MenB disease [1] . Therefore, we investigated the immunogenicity of the rMenB vaccine in a phase II trial, formulated with and without OMVs when administered at 2, 4, 6, and 12 months of age or as a single dose at 12 months of age.
METHODS

Participants.
A phase II, open label, randomized controlled trial was undertaken in the United Kingdom and approved by the National Research Ethics Service (Eudract number 2006-001522-84; ClinicalTrials.gov number NCT00381615). Healthy 2-month-old infants (55-89 days of age, inclusive), with an estimated gestational age у37 weeks, weighing 12.5 kg, and whose parent or legal guardian provided informed consent were enrolled. Infants were excluded if they had previous infection with or close contact with someone infected with MenB, had received vaccination against MenB, had previously received any of the UK infant immunization schedule vaccines, had acute or chronic disease, had experienced previous anaphylactic reactions to vaccine components, had a known or suspected autoimmune disease or impairment, or had received blood products or received or planned to receive nonstudy vaccines.
Procedures. Infants were randomly allocated in a 2:2:1:1 ratio to one of the following groups using a computer-generated randomization list: group I received rMenB vaccine without OMV (rMenB) at 2, 4, 6, and 12 months of age and routine vaccinations; group II received rMenB vaccine with OMVs (rMenB+OMV) at 2, 4, 6, and 12 months of age and routine vaccinations; group III received rMenB at 12 months of age and routine vaccinations; group IV received rMenB+OMV vaccine at 12 months of age and routine vaccinations. Serum samples were obtained at 2, 5, 7, 12, and 13 months of age for groups I and II and at 12 and 13 months of age for groups III and IV. A sample size of 150 was selected to obtain preliminary data on comparative safety and immunogenicity.
Each 0.5-mL rMenB vaccine dose contained 50 mg each of NadA (subvariant 3.1), GNA 2091-fHBP (fHBP subvariant 1.1), and NHBA-GNA 1030 (NHBA subvariant 1.2) adsorbed onto 1.5 mg of aluminium hydroxide. The rMenB+OMV vaccine also contained 25 mg of OMV prepared from the strain NZ 98/ 254 (B:4:P1.7-2,4: ST42: CC41/44). Vaccines were administered by intramuscular injection into the antero-lateral area of the thigh. Vaccination was postponed if the infant had a temperature of у38ЊC (axillary) or had received antibiotic treatment within the previous 7 days.
Concomitant vaccines administered according to the UK immunization schedule were: diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b (Hib) and inactivated poliovirus vaccine (Pediacel: Sanofi Pasteur) at 2, 3, and 4 months of age, pneumococcal conjugate vaccine (Prevenar; Wyeth Pharmaceuticals) at 2, 4, and 13 months of age, meningococcal serogroup C (MenC) conjugate vaccine (Menjugate; Novartis) at 3 and 5 months of age, MenC-Hib conjugate vaccine (Menitorix; GSK Biologicals) at 12 months of age, and measles, mumps, rubella vaccine (Priorix; GSK Biologicals) at 13 months of age.
Safety and tolerability data were collected using a diary card, which was completed on a daily basis for 7 days after each vaccination. Information collected included axillary temperature, any medication administered, local reactions, systemic reactions, any medical attention, and other adverse events. Data on adverse events occurring outside of the diary card period, until study day 481 (18 months of age), were also collected.
Functional antibodies were determined using a standardized SBA assay [15] , incorporating a serum starting dilution of 1: 2 and human serum as an exogenous complement source. Serum samples were assayed against 7 MenB strains, classified in terms of key vaccine antigens (Table 1) . Strains 44/76-SL, NZ 98/254, and 5/99 were used to determine responses against (98) 43 (93) 20 (87) 22 (96) Other 0 (0) 3 (7) 2 (9) 1 (4) NOTE. Data are no. (%) of patients, unless otherwise indicated. Group I received rMenB at 2, 4, 6, and 12 months. Group II received rMenB + OMV at 2, 4, 6, and 12 months. Group III received rMenB at 12 months. Group IV received rMenB + OMV at 12 months. OMV, outer membrane vesicles; rMenB, recombinant serogroup B Neisseria meningitidis vaccine.
fHBP, PorA, and NadA, respectively. Strains from the United Kingdom with diverse variants of vaccine antigens were incorporated to explore likely cross-reactivity of vaccine responses. Expression of vaccine antigens (Table 1) was determined using murine serum samples as described elsewhere [16] . This methodology was limited by the use of serum samples raised against vaccine antigens; therefore, binding was representative of expression in conjunction with any variation in cross-reactivity to heterologous antigens.
Statistical analysis. Immunogenicity was assessed using the per-protocol population. The primary objective was to assess immunogenicity 30 days after the third doses. Secondary objectives were to assess immunogenicity after the second and fourth doses and after a single 12-month dose. Proportions of subjects with putative protective SBA titers у4 [17] and SBA geometric mean titers (GMTs) with 95% confidence intervals (95% CIs) were calculated. Proportions of infants with у4-fold increases in SBA titer from before to 1 month after the second, third, and fourth dose and from before to 6 months after the third dose were also calculated (infants with an SBA titer of !2 before vaccination had to attain a titer of у8 after vaccination to be classed as a у4-fold rise). All analyses were completed by Novartis Vaccines using SAS, version 9.1 (SAS Institute) and were reviewed by an independent statistician. Immunogenicity and safety data were reported descriptively with no formal statistical analysis.
RESULTS
From 21 September 2006 through 28 February 2007, 147 infants
were enrolled (Figure 1 ), of whom 135 (92%) received all vaccinations and completed the final follow-up visit. The 4 groups were similar with respect to demographic characteristics, with the exception of group IV, which had a greater proportion of male subjects (Table 2) .
Immunogenicity primary objective. The rMenB+OMV vaccine demonstrated good immunogenicity 1 month after 3 doses, with 87%, 85%, 95%, and 63% of infants with SBA titers у4 against 44/76-SL (anti-fHBP response), NZ 98/254 (anti-PorA response), 5/99 (anti-NadA response) and M00 242922 (antiPorA response), respectively ( Table 3) . Increases of у5-fold in SBA GMT from before vaccination to 1 month after the third dose were also achieved against these same strains ( Table 4) . Proportions of infants with у4-fold increases in SBA titer from before to 1 month after the third dose were 85%, 78%, 92%, and 53% against 44/76-SL, NZ 98/254, 5/99, and M00 242922, respectively (Table 5 ). Responses were lower against M01 240101, M01 240364, and M01 240355, which expressed diverse vaccine antigens, with 0%-47% and 0%-29% of subjects achieving SBA titers у4-fold and у4-fold increases in SBA titer, respectively. Immunogenicity of the rMenB vaccine after 3 doses was similar to that achieved by the rMenB+OMV vaccine, with the exception of lower responses against NZ 98/254 and M00 242922 (antiPorA response).
Immunogenicity secondary objectives. The rMenB+OMV vaccine demonstrated good immunogenicity after 2 doses, with у64% of subjects with SBA titers у4 against 44/76-SL, NZ 98/ 254, 5/99, and M00 242922. After 2 doses, the rMenB vaccine gave comparable immunogenicity against 5/99 but was less immunogenic against 44/76-SL, NZ 98/254, and M00 242922.
At 6 months after the third dose, SBA GMTs and proportions with SBA titers у4 had decreased against 44/76-SL and 5/99 (rMenB group) and 44/76-SL, NZ 98/254, 5/99, and M00 242922 (rMenB+OMV group). These levels were, how- 
NOTE.
The n values for patient groups are given in Table 3 . OMV, outer membrane vesicles; rMenB, recombinant serogroup B Neisseria meningitidis vaccine.
ever, still elevated compared with those for unvaccinated infants, demonstrating antibody persistence.
After the fourth dose of rMenB+OMV, large increases in SBA GMT were achieved against 44/76-SL, NZ 98/254, 5/99, and M00 240922 (Table 4) . These responses were greater than those achieved after a single dose in the unprimed group, suggesting an anamnestic response. Similar responses were demonstrated after the fourth dose of rMenB against 44/76-SL and 5/99. Proportions of toddlers with SBA titers у4 after the fourth rMenB+OMV dose were 100%, 93%, 96%, and 78% against 44/76-SL, NZ 98/254, 5/99, and M00 242922, respectively. For strains M01 240101 and M01 240364, 57% and 75% of subjects, respectively, had SBA titers у4 after the fourth dose of rMenB+OMV.
Reactogenicity and safety. Both vaccines were generally well tolerated, although the rMenB+OMV vaccine was associated with greater proportions of vaccinees with local reactions of induration and tenderness and local severe reactions (Figure 2). Systemic reaction rates were comparable between the 2 vaccines ( Figure 3 ). In the minority of participants who experienced fever, this was more common after rMenB+OMV than after rMenB. Overall, reports of reactogenicity were similar between groups who received study vaccines and those who received routine vaccines (data not shown). In total, 18 serious adverse events were reported. These consisted of 1 case each of hydrocoele, deafness (presumed congenital), pyrexia, reactive arthritis (knee), wheezing, and purpura and 12 cases of bacterial or viral infections. The transient episode of reactive arthritis developed 1 month after rMenB vaccination and was classified as possibly related to the vaccine. All other serious adverse events were considered by investigators to be unrelated to either study vaccines or routine vaccines. 
DISCUSSION
This trial demonstrated that the investigational rMenB+OMV vaccine was well tolerated and immunogenic against a range of MenB strains when given to healthy infants at 2, 4, and 6 months of age. Furthermore, a booster dose administered at 12 months of age elicited an anamnestic response when compared with a single dose in naive individuals of the same age.
Results from this trial suggest that this vaccine has the potential to provide a broader protection against MenB disease than that provided by existing monovalent OMV vaccines in infants.
We used 44/76-SL, NZ 98/254, and 5/99 to determine responses to the major vaccine components, because they have homologous fHBP, PorA, and a closely related NadA, respectively. Responses against these strains were primarily directed against these specific antigens, because there was no cross-reactivity against the mismatched antigen variants or they did not harbor the NadA gene. Although strains expressed NHBA, this probably had little, if any, impact on results, because this antigen was previously demonstrated not to induce SBA against any of these strains [16] . One limitation of this trial is that it did not incorporate a group receiving OMV vaccine alone; therefore, assessment of the recombinant components of the rMenB+OMV vaccine must be achieved by comparisons with prior OMV vaccine trials.
The fHBP (sub-variant 1.1) vaccine component (rMenB and rMenB+OMV) was immunogenic after both 2 and 3 doses of vaccine, as determined by SBA, against 44/76-SL expressing homologous fHBP. Furthermore, antibody concentrations persisted 6 months after the third dose, and an anamnestic response was demonstrated after the fourth dose. After the 3 primary doses, the fHBP component induced little, if any, cross-reactive response to heterologous sub-variants 1.14 (NZ 98/254), 1.15 (M01 240101), or 1.4 (M00 242922). This is in contrast to preclinical studies, which demonstrated cross-reactive SBA to sub-variants of variant 1 but not to any 2 or 3 variants [18, 19] . Similarly, SBA responses were not induced against strains expressing sub-variant 3.4 (M01 240364 and M01 240355). Varying expression of fHBP could also account for differences in SBA responses, because expression has been reported to vary significantly [18] and correlate with SBA activity [20] . Nevertheless, expression of fHBP was confirmed for all test strains (with the exception of 5/99, which was due to lack of cross reactivity of murine antibody), which suggests that fHBP was likely expressed sufficiently to enable SBA activity if induced antibody was sufficiently cross-reactive.
The NadA vaccine component, as determined by SBA against 5/99, was highly immunogenic after 2 and 3 doses, with SBA persisting through to 12 months of age and eliciting an anamnestic response after the fourth dose. This indicated that the NadA sub-variant 3.1 vaccine component induced a cross-reactive response to sub-variant 2.2 expressed by 5/99 and is in agreement with preclinical data [21] . Despite M01 240364 expressing NadA sub-variant 2.4, which was similar to the subvariant expressed by 5/99 (2.2), SBA responses were lower than those for 5/99. This is likely attributable to the lower NadA expression and not lack of cross-reactivity, because the only difference between these sub-variants is in their leader peptides. Poor responses against M01 240355 are explained by limited cross-reactivity to NadA sub-variant 5.2, which is closely related to NadA variant 4, to which vaccine-induced antibodies are not cross-reactive [22] .
The NHBA component of the rMenB vaccine induced poor SBA responses against NZ 98/254, which expressed the homologous NHBA sub-variant (1.2). Similar responses have been reported after rMenB vaccination in adults [16] which may be attributable in part to the level of expression of NHBA by NZ 98/254. However, the inability of NHBA to inhibit rMenB-or rMenB+OMV-induced SBA against NZ 98/254 or 44/76-SL and 5/99 has been previously reported [16] . It can therefore be assumed that infant SBA activity against these strains in this trial was predominantly attributable to the other vaccine components and not to NHBA. Furthermore, SBA responses against NZ 98/254 and M00 242922 after rMenB+OMV were likely to be attributable to PorA and not to NHBA, because similar responses were not seen with rMenB alone. Additional investigations are required to fully elucidate the immunogenicity of NHBA, which can provide protection in the infant rat model [23] and induce opsonophagocytic activity [24] .
The OMV/PorA component of the rMenB+OMV vaccine demonstrated good immunogenicity after the second and third dose, as determined by SBA against NZ 98/254 and M00 242922 expressing homologous PorA. At 12 months of age, SBA levels had decreased but were still greater than those in groups who had not received rMenB+OMV vaccine. After a fourth dose, an anamnestic response against PorA was indicated (compared with naive individuals who received a single dose). Responses against NZ 98/254 are in close agreement with those previously reported after vaccination with MeNZB at 6 weeks, 3 months, and 5 months, with a booster dose administered at 10 months of age [25] . Responses were confirmed as being directed against the PorA, because only minor increases in SBA were achieved after rMenB against NZ 98/254 and M00 242922. Although expressing an identical PorA, prevaccination SBA levels and vaccine responses against M00 242922 were lower than those achieved against NZ 98/254. This was likely attributable to differences in expression of the many other proteins expressed by the 2 strains, which has been reported to similarly affect SBA titers [15] .
Overall, the rMenB+OMV vaccine demonstrated greater immunogenicity than did the rMenB vaccine. This was most evident for the 2 target strains that harbored the homologous PorA (NZ 98/254 and M00 242922) and attributable to antiPorA SBA. However, greater immunogenicity was also demonstrated at certain time points for 44/76-SL and M01 240101, although it was not determined whether this was attributable to immunity induced by other minor components of the OMV, as previously reported [26] , or because the OMV component enhanced responses to the recombinant antigens. An alternative explanation may be that SBA induced by the rMenB+OMV vaccine act synergistically in comparison with those elicited by the rMenB vaccine alone. Further investigations are required to determine the reasons for the greater immunogenicity of rMenB+OMV. Previous studies of MeNZB in infants and toddlers have shown relatively high rates of reactogenicity [25, 27] . However, both rMenB and rMenB+OMV were generally well tolerated in this trial, with similar reactogenicity rates induced by both vaccines.
Assessment of immunogenicity and estimates of efficacy are complicated by the number of vaccine antigens and the number of naturally occurring variants. Small volumes of serum samples, especially in pediatric trials, limit the number of strains against which the trial serum samples may be assayed. Strains used in this trial provide an insight into the immunogenicity of the vaccines against these antigen variants, but a larger panel of strains is required to fully reveal the breadth of immunity provided by the vaccine. Furthermore, epidemiology of these vaccine antigens among meningococcal populations, which is likely to differ by time and geographical location, must be established. Such studies must include the accurate measurement of expression levels, which can critically affect SBA activity. These epidemiologic and expression data are of paramount importance to enable the prediction of likely coverage of these vaccines, which is currently not feasible.
In this trial, we demonstrated that the rMenB+OMV vaccine was immunogenic and well tolerated, and we confirmed the induction of immune memory. Similar preliminary data have been reported when these vaccines were administered at 6, 8, and 12 months of age [28] . The rMenB+OMV vaccine is currently undergoing analysis in larger safety and immunogenicity trials that, in combination with ongoing epidemiologic and expression studies, will enable further determination of public health benefit. The 3 dose primary schedule studied here would be likely to protect during early infancy, when MenB disease incidence is at its greatest.
